It's A Ten For Humira, AMPE Drubbed By PIVOT Data, CYNA Awaits Data In Q3

Cynapsus Therapeutics Inc.'s (CYNA) pivotal phase III efficacy study of APL-130277 to treat OFF episodes in patients with Parkinson's disease has enrolled the last patient.

from RTT - Biotech http://ift.tt/296MEzf
via IFTTT